Medicare proposes change in anemia drug usage

The Medicare federal health insurance program has proposed removing its requirement that kidney dialysis providers keep patient hemoglobin levels above a set minimum, which could lead to lower use of Epogen, the anemia drug sold by Amgen.

The government health plan said last month that it had no plans to change its reimbursement terms for anemia drugs used to treat kidney patients.

But in a statement on its website on Friday, the agency proposed retiring a requirement that patients'

Medicare proposes change in anemia drug usage